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Key messages
What is already known about this subject?
 ► Inactivated influenza vaccine is recommended 
in patients with autoimmune rheumatic 
diseases to minimise the increased risk 
of influenza and its complications in this 
population.
 ► Concerns about influenza vaccine associating 
with increased risk of autoimmune rheumatic 
disease (AIRD) activity and anecdotal reports of 
the influenza vaccine triggering diseases such 
as vasculitis are barriers to seasonal influenza 
vaccination.
What does this study add?
 ► Seasonal influenza vaccination is not associated 
with AIRD flare and vasculitis.
How might this impact on clinical practice or 
future developments?
 ► This study provides new data on the safety 
of influenza vaccine in people with AIRDs 
and adds to the accumulating evidence to 
support seasonal influenza vaccination in this 
population.
Objectives To examine the association between 
inactivated influenza vaccine (iiV) administration and 
primary care consultation for joint pain, rheumatoid 
arthritis (Ra) flare, corticosteroid prescription, vasculitis 
and unexplained fever in people with autoimmune 
rheumatic diseases (aiRds).
Methods We undertook within-person comparisons 
using self-controlled case-series methodology. aiRd 
cases who received the iiV and had an outcome of 
interest in the same influenza cycle were ascertained 
in clinical practice Research datalink. The influenza 
cycle was partitioned into exposure periods (1–14 days 
prevaccination and 0–14, 15–30, 31–60 and 61–90 
days postvaccination), with the remaining time-period 
classified as non-exposed. incidence rate ratios (iRR) and 
95% ci for different outcomes were calculated.
Results data for 14 928 aiRd cases (69% women, 
80% with Ra) were included. There was no evidence 
for association between vaccination and primary care 
consultation for Ra flare, corticosteroid prescription, fever 
or vasculitis. on the contrary, vaccination associated with 
reduced primary care consultation for joint pain in the 
subsequent 90 days (iRR 0.91 (95% ci 0.87 to 0.94)).
Conclusion This study found no evidence for a 
significant association between vaccination and primary 
care consultation for most surrogates of increased 
disease activity or vaccine adverse-effects in people with 
aiRds. it adds to the accumulating evidence to support 
influenza vaccination in aiRds.
InTROduCTIOn
Autoimmune rheumatic diseases (AIRDs) such as 
rheumatoid arthritis (RA) associate with increased 
risk of influenza and its complications.1 Even 
though inactivated influenza vaccine (IIV) has 
clinical and serological effectiveness in AIRDs, its 
uptake remains suboptimal.2–4 For instance, when 
AIRDs were the sole indication for vaccination, 
49% and 59% people aged 18–44 and 45–64 years, 
respectively, were vaccinated in the 2015–2016 
influenza season in the UK,5 with lower vaccine 
uptake reported in Germany.6
Barriers to IIV include scepticism about effec-
tiveness, concerns about side effects or disease flare 
and reports of vaccination triggering AIRDs such as 
vasculitis.7–11 Trials assessing serological response to 
IIV report stable disease activity following vaccina-
tion provided disease-modifying antirheumatic drugs 
(DMARDs) treatment is continued.12 13 However, 
these studies typically include people with stable 
disease, and, to the best of our knowledge, a real-
world study evaluating the effect of IIV on AIRDs 
has not been performed. Thus, the objectives of this 
study were to investigate the association between IIV 
administration and primary care consultation for 
joint pain, RA flare, new oral corticosteroid prescrip-
tion and potential vaccine adverse effects, such as 
vasculitis and non-infective fever.
MeTHOds
data source
Data were extracted from the Clinical Practice 
Research Datalink (CPRD).14 CPRD is a longitu-
dinal database of anonymised health records of 
>15 million people registered in >700 general 
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Figure 1 Influenza cycle divided into baseline, prevaccination and postvaccination periods. The baseline extended from latest of diagnosis date 
or 1st September in index year to 15 days pre-vaccination,and from 90 days post-vaccination to earliest of 31st August of the next year, date of 
leaving GP surgery, date of death, or latest date of data collection. Exposed period extended from vaccination to 90 days later,and was categorised as 
illustrated above.
practices in the UK. Participants are representative of the UK 
population.14 It contains details of demographics, diagnoses, 
immunisations, prescriptions and lifestyle factors.
study design
Self-controlled case series (SCCS) was developed for assessing 
associations between exposures and outcomes using data from 
participants who develop an outcome of interest and is an 
accepted methodology for vaccine safety studies.15 16 It has the 
advantage of being unaffected by between-person confounding 
as each participant acts as their own control. However, it does 
not account for time varying covariates such as season which 
vary between the unexposed and exposed periods.
source population
Adults aged ≥18 years with RA, spondyloarthritis (SpA) or 
systemic lupus erythematosus (SLE) and prescribed DMARDs.3
study period
The study period was 1 September 2006 to 31 of August 2016. 
This was partitioned into 10 influenza cycles, beginning on 1 
September of 1 year and ending on 31 August the subsequent 
year. Due to the use of non-standard monovalent vaccine along-
side trivalent IIV during 2009–2010 pandemic year, data for 
this year were excluded. Observation periods for each year were 
censored if death, emigration from general practice or last collec-
tion of data from general practice occurred before 31 August of 
the subsequent year.
exposure and outcomes
Vaccination, the exposure of interest, was defined using Read 
codes5 and event dates. Influenza cycles in which a patient was 
coded as having received the IIV elsewhere, for example, at work 
for health care professionals or in community pharmacies were 
excluded from the analysis as the date of vaccination outside 
primary care is not recorded in the CPRD. For cases with >1 
entry for vaccination in an influenza cycle, the earliest record 
was retained.
The outcomes were primary care consultation for:
A. Surrogates of disease activity: joint pain, flare of RA and new 
corticosteroid prescriptions.
B. Vaccine hypersensitivity: vasculitis, non-infective fever. Only 
the first Read code for vasculitis was considered since it is 
a chronic illness, and, participants diagnosed with vasculitis 
before study entry were excluded.
See online supplementary material for details.
exposure and unexposed periods
The influenza cycle was divided into unexposed and exposed 
periods, and the latter was further categorised into smaller time 
periods (figure 1). The first cut-off was selected at 14-day post-
vaccination as it takes 2 weeks for the IIV to induce a serolog-
ical response, and, we hypothesised that this period of immune 
reconstitution was most likely to associate with disease activity.17 
The 14-day period immediately preceding vaccination was 
excluded from the baseline period to minimise confounding due 
to healthy vaccinee effect.18
statistical analyses
SCCS involves fitting a Poisson model conditioned on the 
number of events and calculates incidence rate ratios and 95% 
CI for each exposure period. Distinct SCCS analysis data sets 
were drawn for each outcome. Each participant contributed data 
from one randomly selected eligible influenza cycle in which 
both vaccination and an outcome of interest occurred (online 
supplementary table S1). We analysed data from single randomly 
selected influenza cycle since people who develop an adverse 
outcome temporally closely related to vaccination, for example, 
joint pain within 1–2 weeks of vaccination, will be less likely to 
attend for repeat vaccinations compared to those who have such 
an event after a longer time period. Thus, if vaccination was to 
cause an adverse effect, including data from all influenza cycles 
in which an outcome occurred for a study participant would 
introduce differential bias. Except for vasculitis, >1 event of 
the same type in an influenza cycle were considered as recurrent 
episodes provided the interval between any two consultations 
was ≥15 days.
As corticosteroids are prescribed for many reasons, we 
performed sensitivity analysis restricted to corticosteroid 
prescription on the same day on which there is a primary care 
consultation for joint pain or RA flare. All analyses were carried 
out using Stata V.14.
ResulTs
Data for 14 928 AIRD cases with ≥1 outcome of interest in an 
influenza cycle in which they received the IIV were included. 
Of these, 11 953 (80.07%) had RA, 2347 (15.72%) had SpA 
and 628 (4.21%) had SLE. The majority were female (68.5%) 
and their mean (SD) age was 59 (14) years. Vaccination associ-
ated with fewer primary care consultations for joint pain with 
the magnitude of reduction broadly consistent across the four 
risk periods (table 1). When data for the first 30 days were 
pooled together, vaccination associated with fewer primary care 
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Table 1 Association between IIV and consultation for joint pain, new corticosteroid prescription and RA flare
Outcome Risk period events (n) Person-time (days) IRR (95% CI)* P value*
Joint pain
 
Unexposed 9977 2 712 373 1.00 <0.001
15 days prevaccination 788 160 775 1.29 (1.20 to 1.39)
Postvaccination intervals 
0–14 days 479 150 314 0.84 (0.77 to 0.92) <0.001
15–30 days 567 160 842 0.94 (0.86 to 1.02) 0.127
31–60 days 1121 321 024 0.93 (0.88 to 0.99) 0.025
61–90 days 1069 319 890 0.90 (0.84 to 0.96) 0.001
Corticosteroid
prescription
 
  
Unexposed 9470 2 266 070 1.00 <0.001 
15 days prevaccination 704 135 493 1.21 (1.12 to 1.31)
Postvaccination intervals 
0–14 days 539 126 625 1.00 (0.91 to 1.09) 0.924
15–30 days 554 135 515 0.96 (0.88 to 1.04) 0.338
31–60 days 1151 270 109 1.00 (0.95 to 1.07) 0.876
61–90 days 1182 268 968 1.04 (0.98 to 1.11) 0.184
RA flare
 
  
Unexposed 460 153 247 1.00 0.785 
15 days prevaccination 24 8957 0.95 (0.64 to 1.41)
Postvaccination intervals 
0–14 days 27 8400 0.97 (0.65 to 1.45) 0.888
15–30 days 29 9000 1.12 (0.78 to 1.62 0.525
31–60 days 59 18 000 1.06 (0.80 to 1.39) 0.693
61–90 days 46 17 978 0.81 (0.59 to 1.10) 0.180
*Statistically significant results are in bold (p<0.05).
IIV, inactivated influenza vaccine; IRR, incidence rate ratio; RA, rheumatoid arthritis.
Table 2 Association between inactivated influenza vaccine, vasculitis and unexplained fever*
Outcome Risk period events (n) Person-time (days) Incidence rate ratio (95% CI) P values
Vasculitis
 
Unexposed 89 30 936 1.00 0.906
15 days prevaccination 5 1815 0.95 (0.38 to 2.33)
Postvaccination intervals
  
0–14 days X1 1694 0.41 (0.10 to 1.65) 0.207
15–30 days 5 1815 0.95 (0.38 to 2.33) 0.906
31–60 days 8 3630 0.76 (0.37 to 1.56) 0.453
61–90 days 12 3630 1.14 (0.62 to 2.08) 0.677
Unexplained Unexposed 92 30 735 1.00 0.507 
Fever
  
15 days prevaccination X1 1819 0.71 (0.26 to 1.94)
Postvaccination intervals
  
0–14 days X1 1708 0.71 (0.26 to 1.94) 0.589
15–30 days 6 1830 1.06 (0.28 to 2.07) 0.887
31–60 days 5 3650 0.45 (0.18 to 1.10) 0.079
61–90 days 12 3630 1.09 (0.60 to 1.99) 0.780
X1 fewer than five events in each cell, data suppressed according to Clinical Practice Research Datalink policy.
*Unexplained fever was defined as fever not due to a known cause, for example, infection.
consultations for joint pain (IRR 0.89 (95% CI 0.84 to 0.9)). 
The 14-day prevaccination period associated with significantly 
more primary care consultations for joint pain and new cortico-
steroid prescriptions (table 1). The median (IQR) corticosteroid 
dose was 10 (5–30) mg/day prednisolone equivalents, data avail-
able for 54% prescriptions.
There were no significant associations between vaccination 
and other adverse outcomes in this study (tables 1 and 2). On 
sensitivity analysis, vaccination was not associated with new 
corticosteroid prescription on the same day on which there was 
a primary care consultation for either RA flare or joint pain 
(online supplementary table S2).
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dIsCussIOn
This study reports no significant associations between IIV admin-
istration and new primary-care corticosteroid prescriptions or 
primary care consultations for vasculitis and non-infective fever. 
However, there was a negative association between vaccina-
tion and primary care consultations for joint pain upto 90 days 
postvaccination. Further research is required to understand the 
underlying mechanism. It is unlikely to result from contextual 
response or healthy vaccine effect as there is no prevalent belief 
that vaccination improves AIRD outcomes, and SCCS utilises 
within-person comparisons accounting for the latter. However, 
this observation could result from regression to the mean.
We observed increased primary care consultation for joint pain 
and new corticosteroid prescriptions in the 14 days preceding 
vaccination. This could indicate opportunistic vaccine promo-
tion to people consulting for AIRD flare. Alternatively, this may 
be due to the fact that most influenza vaccinations occur in late 
autumn and winter months5 that coincide with increased AIRD 
activity. It is therefore of interest that the 30-day postvaccination 
period, also in the late autumn and winter months, expected to 
have more consultations for joint pain, had significantly fewer 
consultations.
The potential for vaccines to elicit an immune-mediated 
adverse reaction has raised concerns about a link between 
vaccines and AIRDs.9 10 However, our data do not identify a 
significant association between vaccination and vasculitis and are 
in line with other studies.19 Similarly, there was no association 
between IIV and incident RA in the Epidemiological Investiga-
tion of Rheumatoid Arthritis cohort.20
The main strength of this study is its robust design, employing 
the SCCS method. By performing within-person comparisons, 
it minimises the influence of confounding between individuals, 
a serious problem in observational studies of adverse-effects 
following vaccination. Additionally, the use of consultation and 
prescription data minimised recall bias. The inclusion of a broad 
spectrum of AIRDs makes our findings generalisable. Addition-
ally, we performed sensitivity analysis restricting to corticoste-
roid prescriptions on the same day as primary care consultation 
for either joint pain or RA flare.
However, there are several limitations to this study. First, data 
on disease activity is not recorded in the CPRD, and primary 
care consultations occur at least a few days after flare onset. 
Self-managed flares and those managed by rheumatologists are 
excluded. Thus, the use of consultation-based database under-
estimates the event rate. However, these caveats are unlikely 
to affect the validity of our findings as there is no reason for 
the ratio between events and primary care consultations to vary 
across the influenza-cycle. Our a priori decision to restrict the 
data analysis to one randomly selected influenza-cycle may have 
reduced the power for some outcomes such as new corticoste-
roid prescription which occurred in ≥2 influenza cycles for 50% 
participants. This does not apply to other uncommon outcomes, 
about 90% of which occurred in only one influenza cycle.
In conclusion, this study supports the safety of influenza 
vaccine in AIRDs. These data should be used to address the fear 
of adverse effects from vaccination, an important reason for 
suboptimal uptake of influenza vaccination in AIRDs.
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